| Literature DB >> 32642088 |
Weiyan Ye1, Xiaoli Chen1, Yongbo Huang1, Yuchong Li1, Yonghao Xu1, Zhenting Liang1, Danlin Wu1, Xiaoqing Liu1, Yimin Li1.
Abstract
BACKGROUND: Neutrophil-to-lymphocyte count ratio (NLCR) has been shown as a feasible parameter associated with outcomes of tumor patients and an accessible predictor of bacteremia. However, only a handful of research shed the light on the association between NLCR and outcomes of septic patients. This study is aimed to evaluate the association between NLCR and all-cause mortality in a population of adult septic patients.Entities:
Keywords: Medical Information Mart for Intensive Care (MIMIC); Neutrophil-to-lymphocyte count ratio (NLCR); mortality; sepsis patients
Year: 2020 PMID: 32642088 PMCID: PMC7330395 DOI: 10.21037/jtd-20-1169
Source DB: PubMed Journal: J Thorac Dis ISSN: 2072-1439 Impact factor: 3.005
Figure 1Study cohort. Illustration of inclusion criteria as utilized to select the final cohort of 3,043 patients. MIMIC-III V1.4, Medical Information Mart for Intensive Care III version 1.4; ICU, intensive care units; SICU, surgical intensive care units; MICU, medical intensive care units.
Characteristics of the study patients by NLCR level
| Characteristics | Total (n=3,043) | NLCR levels | P | |||
|---|---|---|---|---|---|---|
| ≤5.89 (n=760) | >5.89, ≤10.69 (n=759) | >10.69, ≤20.25 (n=766) | >20.25 (n=758) | |||
| Demographics | ||||||
| Age (years), median [IQR] | 67 [54, 79] | 63 [51, 78] | 65 [53, 79] | 69 [54, 81] | 69 [57, 81] | <0.001 |
| Gender, n (%) | 0.981 | |||||
| Male | 1,539 (50.6) | 387 (50.9) | 387 (51.0) | 384 (50.1) | 381 (50.3) | |
| Female | 1,504 (49.4) | 373 (49.1) | 372 (49) | 382 (49.9) | 377 (49.7) | |
| Ethnicity, n (%) | 0.001 | |||||
| White | 2,166 (71.2) | 522 (68.7) | 533 (70.2) | 563 (73.5) | 548 (72.3) | |
| Black | 267 (8.8) | 84 (11.1) | 85 (11.2) | 58 (7.6) | 40 (5.3) | |
| Hispanic | 91 (3.0) | 29 (3.8) | 21 (2.8) | 20 (2.6) | 21 (2.8) | |
| Other | 519 (17.1) | 125 (16.4) | 120 (15.8) | 125 (16.3) | 149 (19.7) | |
| Care unit, n (%) | 0.122 | |||||
| SICU | 423 (13.9) | 113 (14.9) | 108 (14.2) | 116 (15.1) | 86 (11.3) | |
| MICU | 2,620 (86.1) | 647 (85.1) | 651 (85.8) | 650 (84.9) | 672 (88.7) | |
| Time, n (%)* | 0.298 | |||||
| ≤6 h | 1,831 (60.2) | 432 (23.6) | 442 (24.1) | 486 (26.5) | 471 (25.7) | |
| >6, ≤12 h | 721 (23.7) | 190 (26.4) | 196 (27.2) | 166 (23.0) | 169 (23.4) | |
| >12, ≤18 h | 339 (11.1) | 95 (28.0) | 85 (25.1) | 79 (23.3) | 80 (23.6) | |
| >18, ≤24 h | 152 (5.0) | 43 (28.3) | 36 (23.7) | 35 (23.0) | 38 (25.0) | |
| Comorbidities, n (%) | ||||||
| AFIB | 789 (25.9) | 158 (20.0) | 201 (26.5) | 195 (25.5) | 235 (31.0) | <0.001 |
| CAD | 443 (14.6) | 86 (11.3) | 99 (13.0) | 132 (17.2) | 126 (16.6) | 0.002 |
| CHF | 899 (29.5) | 182 (23.9) | 222 (29.2) | 247 (32.2) | 248 (32.7) | <0.001 |
| Diabetes | 851 (28.0) | 203 (26.7) | 221 (29.1) | 223 (29.1) | 204 (26.9) | 0.57 |
| Malignancy | 741 (24.4) | 226 (29.7) | 167 (22.0) | 152 (19.8) | 196 (25.9) | <0.001 |
| Liver | 339 (11.1) | 110 (14.5) | 90 (11.9) | 76 (9.9) | 63 (8.3) | 0.001 |
| Renal | 462 (15.2) | 105 (13.8) | 110 (14.5) | 119 (15.5) | 128 (16.9) | 0.367 |
| Laboratory parameters, median [IQR] | ||||||
| Hemoglobin (g/dL) | 10.4 [9.2, 11.8] | 10.1 [8.8, 11.6] | 10.4 [9.4, 11.9] | 10.5 [9.4, 11.9] | 10.5 [9.2, 11.9] | 0.013 |
| Platelet (103/μL) | 199.0 [123.0, 286.0] | 157.0 [88.0, 241.8] | 202 [129.0, 290.0] | 212.5 [144.0, 305.0] | 208.5 [133.0, 305.0] | <0.001 |
| Sodium (mEq/L) | 139 [135, 142] | 139 [136, 142] | 139 [136, 142] | 139 [136, 142] | 138 [135, 141] | 0.264 |
| Potassium (mEq/L) | 4.0 [3.6, 4.5] | 4.0 [3.5, 4.5] | 4.0 [3.6, 4.5] | 4.1 [3.6, 4.5] | 4.1 [3.6, 4.6] | 0.022 |
| Bicarbonate (mEq/L) | 22 [19, 25] | 22 [19, 26] | 22 [19, 25] | 22 [19, 25] | 21 [18, 25] | 0.005 |
| Chloride (mEq/L) | 106 [101, 110] | 106 [102, 111] | 106 [101, 110] | 106 [101, 110] | 105 [100, 109] | 0.086 |
| White blood cell (103/μL) | 12.3 [8.1, 18.1] | 7.8 [4.2, 11.4] | 11.4 [8.0, 20.3] | 13.9 [10.1, 18.8] | 17.6 [12.1, 24.8] | <0.001 |
| Neutrophil (103/μL) | 9.9 [6.2, 15.0] | 5.0 [2.3, 7.6] | 9.2 [6.5, 12.4] | 12.0 [8.6, 16.0] | 15.4 [10.4, 21.2] | <0.001 |
| Lymphocyte (103/μL) | 0.9 [0.5, 1.4] | 1.4 [0.8, 2.1] | 1.2 [0.8, 1.5] | 0.8 [0.6, 1.1] | 0.4 [0.3, 0.6] | <0.001 |
| Creatinine (mg/dL) | 1.2 [0.8, 2.1] | 1.1 [0.7, 1.8] | 1.2 [0.8, 2.0] | 1.2 [0.8, 2.0] | 1.4 [0.9, 2.3] | <0.001 |
| Scoring systems, median [IQR] | ||||||
| SOFA | 6 [4, 8] | 6 [3, 9] | 5 [3, 8] | 5 [3, 8] | 6 [4, 9] | <0.001 |
| SAPSII | 41 [33, 53] | 39 [31, 51] | 40 [31, 51] | 42 [33, 52] | 46 [36, 56] | <0.001 |
*, time interval of complete blood count test after admission. NLCR, neutrophil-to-lymphocyte count ratio; SICU, surgical intensive care units; MICU, medical intensive care units; AFIB, atrial fibrillation; CAD, coronary artery disease; CHF, congestive heart failure; SOFA, sequential organ failure assessment; SAPSII, simplified acute physiology score II; IQR, interquartile range.
Outcomes of patients according to the quartiles of NLCR quartiles
| Outcome | Total (n=3,043) | First quartile (n=760) | Second quartile (n=759) | Third quartile (n=766) | Fourth quartile (n=758) | P |
|---|---|---|---|---|---|---|
| Mortality, n (%) | ||||||
| 7-day | 387 (12.7) | 101 (13.3) | 75 (9.9) | 104 (13.6) | 107 (14.1) | 0.064 |
| 28-day | 809 (26.6) | 179 (23.6) | 167 (22.0) | 203 (26.5) | 260 (34.3) | <0.001 |
| ICU | 513 (16.9) | 124 (16.3) | 97 (12.8) | 128 (16.7) | 164 (21.6) | <0.001 |
| Hospital | 724 (23.8) | 166 (21.8) | 146 (19.2) | 181 (23.6) | 231 (30.5) | <0.001 |
| Length of stay, median (IQR) | ||||||
| ICU, days | 3.7 (1.9, 8.1) | 3.1 (1.7, 4.5) | 3.5 (1.8, 8.5) | 3.7 (2.0, 8.1) | 4.4 (2.3, 8.8) | <0.001 |
NLCR, neutrophil-to-lymphocyte count ratio; ICU, intensive care units; IQR, interquartile range.
Figure 2Kaplan-Meier curves showing the association between the NLCR quartiles and the 28-day mortality. ICU, intensive care units; NLCR, neutrophil-to-lymphocyte count ratio.
Cox proportional hazard models exploring the association of NLCR quartiles with 28-day mortality
| Factor | Univariate model | Multivariate model | |||
|---|---|---|---|---|---|
| Hazard ratio (95% CI) | P | Hazard ratio (95% CI) | P | ||
| Age (years) | |||||
| ≤45 | Reference | – | Reference | – | |
| >45, ≤64 | 1.65 (1.24, 2.20) | 0.001 | 1.17 (0.87, 1.57) | 0.291 | |
| >64, ≤90 | 2.17 (1.66, 2.85) | <0.001 | 1.40 (1.04, 1.87) | 0.025 | |
| >90 | 2.41 (1.71, 3.42) | <0.001 | 1.80 (1.25, 2.61) | 0.002 | |
| Gender (male) | 1.11 (0.97, 1.27) | 0.143 | – | – | |
| Ethnicity | |||||
| White | Reference | – | Reference | – | |
| Black | 0.95 (0.73, 1.23) | 0.705 | 0.94 (0.72, 1.22) | 0.637 | |
| Hispanic | 0.80 (0.51, 1.26) | 0.333 | 1.02 (0.64, 1.61) | 0.940 | |
| Other | 1.45 (1.23, 1.72) | <0.001 | 1.45 (1.22, 1.72) | <0.001 | |
| Time* | |||||
| ≤6 h | Reference | – | – | – | |
| >6, ≤12 h | 1.04 (0.88, 1.22) | 0.674 | – | – | |
| >12, ≤18 h | 1.07 (0.86, 1.34) | 0.527 | – | – | |
| >18, ≤24 h | 1.14 (0.83, 1.55) | 0.423 | – | – | |
| Care unit (MICU) | 0.69 (0.55, 0.86) | 0.001 | 0.79 (0.63, 0.99) | 0.043 | |
| Comorbidities | |||||
| AFIB | 1.44 (1.24, 1.66) | <0.001 | Not selected | – | |
| CAD | 1.06 (0.88, 1.29) | 0.538 | – | – | |
| CHF | 1.18 (1.02, 1.36) | 0.029 | Not selected | ||
| Diabetes | 0.95 (0.81, 1.10) | 0.474 | – | – | |
| Malignancy | 1.74 (1.50, 2.01) | <0.001 | 1.59 (1.36, 1.85) | <0.001 | |
| Liver | 1.88 (1.57, 2.26) | <0.001 | 1.92 (1.57, 2.36) | <0.001 | |
| Renal | 1.07 (0.89, 1.30) | 0.453 | – | – | |
| Laboratory parameters | |||||
| Hemoglobin | 0.92 (0.89, 0.96) | <0.001 | 0.96 (0.93, 1.00) | 0.024 | |
| Platelet | 1.00 (1.00, 1.00) | 0.010 | Not selected | – | |
| Sodium | 0.99 (0.98, 1.01) | 0.316 | – | – | |
| Potassium | 1.30 (1.21, 1.41) | <0.001 | 1.17 (1.08, 1.27) | <0.001 | |
| Bicarbonate | 0.95 (0.94, 0.97) | <0.001 | Not selected | – | |
| Chloride | 0.99 (0.98, 1.00) | 0.197 | – | – | |
| Creatinine | 1.08 (1.05, 1.12) | <0.001 | 0.92 (0.88, 0.97) | 0.001 | |
| White Blood Cell | 1.01 (1.00, 1.01) | <0.001 | Not selected | – | |
| Neutrophil | 1.01 (1.01, 1.02) | <0.001 | Not selected | – | |
| Lymphocyte | 0.96 (0.91, 1.02) | 0.170 | – | – | |
| Scoring system | |||||
| SOFA | 1.18 (1.16, 1.20) | <0.001 | 1.06 (1.03, 1.09) | <0.001 | |
| SAPSII | 1.05 (1.05, 1.06) | <0.001 | 1.04 (1.03, 1.05) | <0.001 | |
| NLCR | |||||
| First quartile | Reference | – | Reference | – | |
| Second quartile | 0.91 (0.74, 1.13) | 0.391 | 0.92 (0.75, 1.14) | 0.460 | |
| Third quartile | 1.14 (0.93, 1.39) | 0.202 | 1.18 (0.96, 1.45) | 0.112 | |
| Fourth quartile | 1.50 (1.24, 1.82) | <0.001 | 1.22 (1.01, 1.49) | 0.046 | |
*, time interval of complete blood count test after admission. MICU, medical intensive care units; AFIB, atrial fibrillation; CAD, coronary artery disease; CHF, congestive heart failure; SOFA, sequential organ failure assessment; SAPSII, simplified acute physiology score II; NLCR, neutrophil-to-lymphocyte count ratio; CI, confidence interval.
Figure 3Receiver operating characteristic curves for the best neutrophil-to-lymphocyte count ratio (NLCR) thresholds to predict 28-day mortality. SOFA, sequential organ failure assessment; SAPSII, simplified acute physiology score II.
Subgroup analysis of the associations between NLCR and 28-day mortality
| Characteristics | No. of patients | NLRC | P | |||
|---|---|---|---|---|---|---|
| ≤5.89 | >5.89, ≤10.69, HR (95% CI) | >10.69, ≤20.25, HR (95% CI) | >20.25, HR (95% CI) | |||
| Age (years) | 0.313 | |||||
| ≤45 | 385 | 1.0 (ref) | 0.56 (0.27, 1.15) | 0.51 (0.24, 1.07) | 1.15 (0.60, 2.20) | |
| >45, ≤64 | 966 | 1.0 (ref) | 0.65 (0.46, 0.93) | 0.75 (0.53, 1.06) | 0.86 (0.60, 1.23) | |
| >64, ≤90 | 1,462 | 1.0 (ref) | 0.86 (0.64, 1.16) | 1.06 (0.81, 1.40) | 1.46 (1.13, 1.90) | |
| >90 | 206 | 1.0 (ref) | 0.66 (0.30, 1.4) | 1.30 (0.65, 2.53) | 1.11 (0.56, 2.22) | |
| Gender | 0.238 | |||||
| Female | 1,496 | 1.0 (ref) | 0.98 (0.72, 1.33) | 1.02 (0.75, 1.37) | 1.62 (1.23, 2.13) | |
| Male | 1,527 | 1.0 (ref) | 0.86 (0.64, 1.15) | 1.26 (0.96, 1.65) | 1.41 (1.08, 1.83) | |
| AFIB | 0.859 | |||||
| Yes | 785 | 1.0 (ref) | 0.90 (0.60, 1.33) | 1.27 (0.88, 1.85) | 1.51 (1.06, 2.15) | |
| No | 2,238 | 1.0 (ref) | 0.90 (0.70, 1.15) | 1.07 (0.84, 1.36) | 1.44 (1.15, 1.81) | |
| CAD | 0.261 | |||||
| Yes | 439 | 1.0 (ref) | 1.38 (0.74, 2.58) | 1.39 (0.76, 2.53) | 2.39 (1.36, 4.21) | |
| No | 2,584 | 1.0 (ref) | 0.87 (0.69, 1.08) | 1.12 (0.91, 1.39) | 1.40 (1.14, 1.72) | |
| CHF | 0.796 | |||||
| Yes | 893 | 1.0 (ref) | 0.89 (0.53, 1.52) | 0.89 (0.53, 1.47) | 1.05 (0.64, 1.72) | |
| No | 2,130 | 1.0 (ref) | 0.95 (0.74, 1.21) | 1.18 (0.93, 1.50) | 1.48 (1.17, 1.86) | |
| Diabetes | 0.738 | |||||
| Yes | 846 | 1.0 (ref) | 0.80 (0.53, 1.19) | 1.00 (0.68, 1.47) | 1.49 (1.03, 2.14) | |
| No | 2,177 | 1.0 (ref) | 0.96 (0.75, 1.23) | 1.21 (0.95, 1.53) | 1.52 (1.21, 1.90) | |
| Malignancy | 0.844 | |||||
| Yes | 734 | 1.0 (ref) | 0.92 (0.64, 1.32) | 1.21 (0.86, 1.72) | 1.69 (1.25, 2.30) | |
| No | 2,289 | 1.0 (ref) | 0.97 (0.75, 1.26) | 1.20 (0.94, 1.54) | 1.48 (1.16, 1.89) | |
| Liver | 0.269 | |||||
| Yes | 335 | 1.0 (ref) | 1.00 (0.64, 1.55) | 1.26 (0.80, 1.98) | 1..13 (0.70, 1.83) | |
| No | 2,688 | 1.0 (ref) | 0.92 (0.72, 1.17) | 1.18 (0.94, 1.48) | 1.67 (1.35, 2.07) | |
| Renal | 0.502 | |||||
| Yes | 458 | 1.0 (ref) | 1.00 (0.56, 1.80) | 1.55 (0.91, 2.64) | 2.00 (1.21, 3.30) | |
| No | 2,565 | 1.0 (ref) | 0.90 (0.72, 1.13) | 1.08 (0.87, 1.35) | 1.43 (1.16, 1.76) | |
| Hemoglobin (g/dL) | 0.026 | |||||
| <11 | 1,905 | 1.0 (ref) | 0.95 (0.73, 1.24) | 1.41 (1.11, 1.79) | 1.68 (1.33, 2.12) | |
| ≥16 | 1,115 | 1.0 (ref) | 0.85 (0.59, 1.21) | 0.75 (0.52, 1.09) | 1.20 (0.86, 1.67) | |
| Platelet (103/μL) | 0.207 | |||||
| <100 | 555 | 1.0 (ref) | 1.03 (0.71, 1.48) | 1.11 (0.75, 1.63) | 1.14 (0.79, 1.64) | |
| ≥100, ≤300 | 1,785 | 1.0 (ref) | 1.00 (0.73, 1.35) | 1.22 (0.91, 1.63) | 1.70 (1.29, 2.24) | |
| >300 | 680 | 1.0 (ref) | 1.14 (0.65, 1.98) | 1.81 (1.08, 3.03) | 2.46 (1.49, 4.05) | |
| Sodium | 0.778 | |||||
| <135 | 614 | 1.0 (ref) | 0.87 (0.56, 1.33) | 0.91 (0.59, 1.42) | 1.47 (1.01, 2.14) | |
| ≥135, ≤145 | 2,116 | 1.0 (ref) | 0.93 (0.71, 1.21) | 1.19 (0.93, 1.53) | 1.47 (1.16, 1.88) | |
| >145 | 291 | 1.0 (ref) | 0.88 (0.51, 1.54) | 1.47 (0.87, 2.50) | 1.75 (1.02, 2.99) | |
| Potassium (mEq/L) | 0.095 | |||||
| <3.5 | 504 | 1.0 (ref) | 1.04 (0.58, 1.89) | 1.19 (0.69, 2.08) | 1.70 (1.01, 2.87) | |
| ≥3.5, ≤5.5 | 2,358 | 1.0 (ref) | 0.89 (.70, 1.13) | 1.21 (0.97, 1.51) | 1.55 (1.25, 1.92) | |
| >5.5 | 159 | 1.0 (ref) | 0.72 (0.36, 1.43) | 0.39 (0.17, 0.89) | 0.66 (0.33, 1.35) | |
| Bicarbonate (mEq/L) | 0.009 | |||||
| <21.4 | 1,405 | 1.0 (ref) | 0.84 (0.63, 1.12) | 1.04 (0.80, 1.35) | 1.04 (0.80, 1.35) | |
| ≥21.4, ≤27.3 | 1,167 | 1.0 (ref) | 0.94 (0.66, 1.34) | 1.10 (0.77, 1.57) | 2.04 (1.48, 2.81) | |
| >27.3 | 448 | 1.0 (ref) | 1.13 (0.60, 2.12) | 1.42 (0.77, 2.61) | 2.43 (1.38, 4.25) | |
| Chloride (mEq/L) | 0.499 | |||||
| <96 | 208 | 1.0 (ref) | 0.71 (0.35, 1.43) | 0.71 (0.32, 1.54) | 1.22 (0.65, 2.27) | |
| ≥96, ≤106 | 1,466 | 1.0 (ref) | 0.88 (0.64, 1.19) | 1.13 (0.85, 1.51) | 1.65 (1.27, 2.17) | |
| >106 | 1,350 | 1.0 (ref) | 0.98 (0.71, 1.34) | 1.23 (0.91, 1.67) | 1.32 (0.97, 1.78) | |
| Creatinine (mg/dL) | 0.025 | |||||
| <0.5 | 124 | 1.0 (ref) | 1.17 (0.34, 4.03) | 1.78 (0.56, 5.60) | 4.61 (1.66, 12.81) | |
| ≥0.5, ≤1.2 | 1,445 | 1.0 (ref) | 0.96 (0.69, 1.34) | 1.13 (0.81, 1.58) | 1.84 (1.36, 2.50) | |
| >1.2 | 1,452 | 1.0 (ref) | 0.85 (0.64, 1.12) | 1.05 (0.81, 1.36) | 1.12 (0.87, 1.43) | |
| SOFA score | 0.002 | |||||
| <5 | 1,136 | 1.0 (ref) | 1.35 (0.81, 2.26) | 2.08 (1.28, 3.37) | 3.19 (1.97, 5.15) | |
| ≥5 | 1,887 | 1.0 (ref) | 0.88 (0.70, 1.11) | 1.02 (0.82, 1.28) | 1.16 (0.94, 1.43) | |
| SAPSII | 0.003 | |||||
| <40 | 1,352 | 1.0 (ref) | 1.37 (0.83, 2.26) | 1.51 (0.91, 2.50) | 2.71 (1.70, 4.34) | |
| ≥40 | 1,671 | 1.0 (ref) | 0.80 (0.63, 1.01) | 0.93 (0.75, 1.16) | 1.03 (0.84, 1.27) | |
AFIB, atrial fibrillation; CAD, coronary artery disease; CHF, congestive heart failure; SOFA, sequential organ failure assessment; SAPSII, simplified acute physiology score II; NLCR, neutrophil-to-lymphocyte count ratio.